Dezhan Healthcare's affiliated company Dongfang Lue has received approval for clinical trials for a new indication in a collaborative research and development project.

Dezhan Healthcare (000813.SZ) announced that the company recently received a notification letter from its equity joint venture company, Beijing Dongfang Le Biopharmaceutical Technology Co., Ltd. (referred to as "Dongfang Le"), which recently received approval from the National Medical Products Administration (NMPA) for its clinical trial approval notice for drug (with reference number 2025LP00346). The approval is for the clinical trial application of VGX-3100 project, developed in collaboration with Inovio Pharmaceuticals, Inc. (referred to as "Inovio"), targeting HPV-16/18 related vaginal intraepithelial neoplasm II.